ATROPINE (AUTOINJECTOR)
Peakatropine injection, 2 mg
NDAINTRAMUSCULARSOLUTIONPriority Review
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
ATROPINE (AUTOINJECTOR) (atropine injection, 2 mg) is cholinergic antagonists [moa]. Approved for poisoning by susceptible organophosphorus nerve agents having anticholinesterase activity, carbamate insecticides in adults. First approved in 2018.
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Atropine Autoinjector is a 2 mg intramuscular injection formulation of atropine, an anticholinergic agent that acts as a cholinergic antagonist. It is indicated for emergency treatment of poisoning by organophosphorus nerve agents and carbamate insecticides in adults. The drug rapidly blocks acetylcholine receptors to reverse cholinergic overstimulation caused by these toxins.
Peak
Peak lifecycle stage indicates stable market position with established demand; team size likely moderate and focused on maintenance rather than aggressive growth.
Mechanism of Action
Cholinergic Antagonists
Pharmacologic Class:
Anticholinergic
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.